LEITAT is a Technology Center which aims to provide technological solutions to the industry, adding value to both technological products and processes. The Biomed division is the unit of the LEITAT Technological Centre dedicated to oncology research. The basic aim of Biomed is the identification of new oncology targets and the generation of new molecular entities and specially monoclonal antibodies (MAb) to modulate them, and characterize its in vitro & in vivo activity profiles in order to deliver these innovative drugs as clinical development candidates.
Role/activity of organisation in the project
The activities performed by Biomed division in LEITAT are to generate and produce monoclonal antibodies for specific bring the therapeutic nanoparticles to the tumour cells. On the other hand, the Biomed division of LEITAT is also contributing to the project by providing in vitro and in vivo models to obtain the proof-of-concept of the nanoparticles for therapy and diagnosis.
Key people involved in the project
Dr. Francesc Mitjans, Ph.D. biologist (1986, Barcelona University, Faculty of Biology) he was finalist of the the award of the University of Barcelona, the Doctor Senate Prize. He was Project Leader, Laboratory Head, and Department Head in Merck Farma y Química, the Spanish Merck KGaA subsidiary. He developed pre-clinical projects and leaded the achievement of phase I clinical trials for new anti-tumour drugs. Currently he is manager of the Biomed Division of LEITAT Technological Centre.
Jaume Adan, biologist (1983, Barcelona Autonomous University, Faculty of Biology). He was Project Leader and Laboratory Head in Merck Farma y Química, the Spanish Merck KGaA subsidiary. He was responsible of the Monoclonal Antibody Generation Unit and was also responsible of several pre-clinical projects in oncology. Currently he is project manager of the Biomed Division of LEITAT Technological Centre.
Marc Masa, biologist (1999, Barcelona University, Faculty of Biology) he has a strong background in bioinformatics and business intelligence. He was Project Leader and co-coordinator of new Target Candidates for Drug Development in Merck Farma y Química. He had conducted several target-proposal projects, benchmarking and bioinformatic support to all steered projects: target discovery and lead discovery/optimization at Merck. At present, he is project manager of the Biomed Divison of LEITAT Technological Center.
Recent publications / patents
1. Marchán S, Pérez-Torras S, Vidal A, Adan J, Mitjans F, Carbó N, Mazo A. Dual effects of β3 integrin subunit expression on human pancreatic cancer models. Anal Cell Pathol (Amst). 2010 Oct 26.
2. Cupido T, Spengler J, Ruiz-Rodriguez J, Adan J, Mitjans F, Piulats J, Albericio F. Amide-to-ester substitution allows fine-tuning of the cyclopeptide conformational ensemble. Angew Chem Int Ed Engl. 2010 Apr 1;49(15):2732-7
3. Mencía N, Selga E, Rico I, de Almagro MC, Villalobos X, Ramirez S, Adan J, Hernández JL, Noé V, Ciudad CJ. Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer. 2010 Jun 1;10:250
4. Vizán, P., S. Sánchez-Tena, G. Alcarraz-Vizán, M. Soler, R. Messeguer, M.D. Pujol, W-N. Paul Lee, M. Cascante. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis. 2009; 30(6):946-52.
5. Roca, R.Messeguer R. Genómica (2009). In: Biotechnology and Drugs. Ed. Consejo General de Colegios Oficiales de Farmacéuticos. p.p. 17-43.
6. Masa M. Genómica (2009). In: Biotechnology and Drugs. Ed. Consejo General de Colegios Oficiales de Farmacéuticos. p.p. 117-142.
7. Piulats J, Mitjans F. “Angiogenic switch pathways" in Principles of Molecular Oncology, 2007 (3d Edition), p.p. 411-441. Eds: Miguel H Bronchud, MaryAnn Foote. Springer Press. New York.
8. F. Mitjans, J. Piulats. Clinical implications of basic research. Angiogenesis: target new cancer treatments. Gastroenterología y Hepatología Continuada. 2007. 6(1): 27-31.
9. Bosch B, Clotet-Codina I, Blanco J, Pauls E, Coma G, Cedeno S, Mitjans F, Llano A, Bofill M, Clotet B, Piulats J, Este JA. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res. 2006 March; 69(3):173-80.
10. Fernandez Y, Queralt J, PAvía X, Piera C, Ramírez de Arellano I, Mitjans F, Messeguer R, Piulats J, Carrió I. Multitracer in vivo assessment of tumor models with 18F-fluorothymidine, 18FFDG and N-ammonia PET in mice. Eur J Nucl Med Mol Imaging 2006, 33 (supl II): S249.
11. Enns A, Korb T, Schluter K, Gassmann P, Spiegel HU, Senninger N, Mitjans F, Haier J. Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer. 2005 May; 41(7):1065-72.